Famed boot manufacturer Dr. Martens is anticipating a significant financial setback due to the impact of US tariffs this year. The company, known for its iconic yellow-stitched boots, has disclosed that it foresees a multimillion-pound impact on its profits as a result of increased import duties on footwear manufactured in Vietnam, a shift made in response to the trade war initiated by US President Donald Trump.
Dr. Martens has proactively restructured its supply chain, moving away from China, which formerly accounted for half of its production, to mitigate the impact of higher US import tariffs. Despite the looming tariff challenges, the company remains optimistic about meeting its full-year profit forecasts ranging from £53 million to £60 million in underlying pre-tax profits.
Following this announcement, Dr. Martens’ stock prices experienced a sharp decline, plummeting more than 10% during early trading on Thursday. The company has outlined plans to fully counterbalance the additional tariff expenses starting from the next fiscal year through stringent cost management, adaptable product sourcing, and strategic adjustments to pricing policies in the USA.
In the midst of addressing tariff concerns, Dr. Martens reported a reduction in losses to £11 million for the first half of the fiscal year, compared to £12.3 million in the previous year, with a 0.8% sales increase totaling £327.3 million. CEO Ije Nwokorie expressed confidence in the brand’s resilience, highlighting positive sales growth and successful product launches.
Investment director Russ Mould from broker AJ Bell noted Dr. Martens’ gradual progress towards profitability, emphasizing improvements in sales strategies and a more robust performance in the American market. Despite positive indicators in the half-year results, investor reaction was subdued, reflected in the initial decline in share value, signaling ongoing market uncertainty and cautious investor sentiment.